Views 408
Citations 0
Invited Commentary
February 2014

Data From ACS NSQIP on CRS-HIPECCan They Cool Off the Controversies?

Author Affiliations
  • 1Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Surg. 2014;149(2):176. doi:10.1001/jamasurg.2013.3665

Jafari et al1 should be congratulated on their timely report of the short-term morbidity and mortality of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in this issue of JAMA Surgery. Their data highlight the low mortality and acceptable morbidity from American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) hospitals. Moreover, these outcomes are important because they relate the experience of a broad spectrum of centers performing this radical intervention. However, what the study lacks are the answers to the unresolved questions and controversies regarding optimal patient selection and methodology of HIPEC.

First Page Preview View Large
First page PDF preview
First page PDF preview